BRIEF—CanSino and Pfizer terminate vaccine deal

China’s CanSino Biologics and US pharma giant Pfizer announced on June 4 that they had terminated a 10-year partnership signed in 2020.

The partnership allowed Pfizer to exclusively promote the Tianji n-based biotech’s proprietary meningococcal ACWY vaccine Menhycia in China.

The reason for the termination was not disclosed in the statement.

CanSino said the company has established a team to take over Pfizer’s work.

So far, no sales of Menhycia have been generated.

Pfizer’s meningococcal B vaccine Trumenba is not sold in China, which currently only offers meningococcal AC vaccines in the country.

Chinese parents who wish to inoculate their children with a meningococcal B vaccine would have to travel to Hong Kong to get GSK’s Bexsero.